Workflow
天坛生物(600161) - 2014 Q4 - 年度财报
BTBPBTBP(SH:600161)2015-03-23 16:00

Financial Performance - In 2014, the company's operating revenue was CNY 1,826,551,127.27, a decrease of 0.54% compared to CNY 1,836,504,083.00 in 2013[24]. - The net profit attributable to shareholders was CNY 128,391,673.34, down 65.49% from CNY 372,028,783.90 in the previous year[24]. - The basic earnings per share decreased to CNY 0.25, a decline of 65.49% from CNY 0.72 in 2013[26]. - Operating profit was CNY 284.90 million, down 46.97% from CNY 537.26 million year-on-year[31]. - The company reported a significant increase in management expenses, which rose to CNY 433,172,783.91 from CNY 261,475,318.20, reflecting higher operational costs[165]. - The total profit for the year 2014 was CNY 41,787,957.92, a decrease from CNY 305,923,171.89 in the previous year[169]. - The net profit for 2014 was CNY 32,150,606.90, compared to CNY 283,236,207.69 in 2013, reflecting a significant decline[169]. - The company reported a total comprehensive income for the year of CNY 29,340,606.90, compared to CNY 283,236,207.69 in 2013[169]. Assets and Liabilities - The total assets at the end of 2014 were CNY 6,015,448,417.52, an increase of 6.76% from CNY 5,634,539,142.00 in 2013[25]. - Total liabilities increased to CNY 3,797,815,808.06 from CNY 3,458,214,420.35, an increase of approximately 9.8%[159]. - The company's equity attributable to shareholders increased to CNY 1,940,976,931.75 from CNY 1,926,034,355.38, a growth of approximately 0.8%[159]. - Current assets rose to CNY 2,079,827,741.60 from CNY 1,948,972,718.55, marking an increase of about 6.7%[157]. - The total current liabilities increased to CNY 2,550,969,630.67 from CNY 1,848,919,382.97, marking an increase of about 37.9%[158]. Cash Flow - The cash flow from operating activities was CNY 477,952,523.13, a decrease of 15.62% compared to CNY 566,433,984.53 in 2013[24]. - Cash flow from investing activities increased by 7.71% to CNY -461.78 million, mainly due to reduced capital expenditures on the Yizhuang project[43]. - Cash flow from financing activities rose by 30.68% to CNY 271.37 million, driven by increased borrowings[43]. - The net cash flow from financing activities was CNY 271,369,120.97, an increase from CNY 207,651,573.09 in 2013[172]. Research and Development - Research and development expenses totaled CNY 94.97 million, representing 5.20% of operating revenue and 4.28% of net assets[41]. - The company received clinical research approval for several vaccines, including the OPV and IPV, enhancing its product pipeline[44]. - The company is investing heavily in R&D, with a budget increase of 25% aimed at developing new technologies and enhancing existing product lines[114]. - Research and development investments have increased by 30%, totaling 300 million, aimed at enhancing product efficacy and safety[115]. Market Position and Strategy - The company aims to lead the domestic vaccine market and establish blood products as a benchmark in China, with a focus on entering international markets[70]. - The biopharmaceutical industry in China is expected to grow rapidly, driven by increasing domestic demand and government policies, with significant growth potential compared to international markets[68]. - The company is exploring strategic acquisitions to bolster its market position, with potential targets identified that could add 100 million in annual revenue[114]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[115]. Governance and Compliance - The company has revised its governance documents, including the Articles of Association and management guidelines for senior executives, to ensure compliance with regulatory requirements[129]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independent representation[131]. - The company has implemented a strict insider information management system to control the dissemination of sensitive information[133]. - The company respects the rights of stakeholders, including creditors and employees, promoting sustainable development[132]. Employee and Management - The total number of employees in the parent company is 1,208, while the total number of employees in major subsidiaries is 1,521, resulting in a combined total of 2,729 employees[124]. - The company implements a performance-based salary system for employees, which includes base salary, performance pay, and various bonuses[125]. - Training programs are established to enhance employee skills and adapt to new market conditions, focusing on quality assurance, operational skills, and risk management[126]. - The total remuneration for the board members and senior management during the reporting period amounted to 620.54 million CNY before tax[113].